Merrion Pharma claimed that the enhancers covered by the patent have the ability to enhance oral absorption many fold compared to standard formulations. The technology can therefore be used to enable oral (tablet) administration of compounds that are normally administered only as injectables, usually in hospital or clinic settings.
Merrion Pharma said that the efficacy, safety and side effect profiles of drugs can be improved substantially using this delivery technology. In addition the new products developed have potential for Quality of Life improvements for patients and substantial economic improvements for hard pressed healthcare systems.
John Lynch, CEO of Merrion, said: “This is a significant development for Merrion’s Gipet technology. The continued growth of our patent estate, further establishes us as one of the leading companies in this space.
“Merrion’s Gipet technology has been validated in several products, demonstrating that we deliver real value to patients and healthcare providers. For example, Orazol, our lead pipeline product, showed excellent results in a Phase IIb study published at last year’s meeting of the American Society of Clinical Oncology (ASCO). This US patent is another step towards achieving our overall vision.”